Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terbogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 20/20 | 0.74 |
| ▸ | TBXAS1 known ✓ | P24557 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbogrel SCHEMBL27132959 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL2924124 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL2924118 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL15413064 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL42849 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537036 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL31680499 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL15413066 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL29383187 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537032 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| WO-2023055751-A1 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-06 | — | — | WO | claimed |
| US-11421234-B2 | Aptamers for targeting coagulation factor XIII and uses thereof | CHANG GUNG UNIVERSITY (TW) | 2022-08-23 | — | — | US | claimed |
| US-20210163945-A1 | APTAMERS FOR TARGETING COAGULATION FACTOR XIII AND USES THEREOF | CHANG GUNG UNIVERSITY (TW) | 2021-06-03 | — | — | US | claimed |
| US-20210146003-A1 | A NOVEL METHOD TO IMPROVE ADHESIVE STRENGTH OF REVERSIBLE POLYMERS AND HYDROGELS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-05-20 | — | — | US | claimed |
| WO-2018232384-A1 | A NOVEL METHOD TO IMPROVE ADHESIVE STRENGTH OF REVERSIBLE POLYMERS AND HYDROGELS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-9994901-B2 | Pro-inflammatory mediators in diagnosis and treatment of chronic obstructive pulmonary disease | NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION (US) | 2018-06-12 | — | — | US | claimed |
| EP-3094381-A1 | PLATELET DECOYS AND USE THEREOF | President and Fellows of Harvard College (US) | 2016-11-23 | — | — | EP | claimed |
| WO-2015109220-A1 | PLATELET DECOY AND USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006100213-A1 | COMPOSITION COMPRISING A COMBINED THROMBOXANE RECEPTOR ANTAGONIST AND THROMBOXANE SYNTHASE INHIBITOR AND A COX-2 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | WO | claimed |
| US-20060217431-A1 | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | claimed |
| US-20060160165-A1 | Device and methods for identifying and treating aspirin non-responsive patients | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006066008-A2 | DEVICE AND METHODS FOR IDENTIFYING AND TREATING ASPIRIN NON-RESPONSIVE PATIENTS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1663162-A2 | ORALLY ADMINISTRABLE DOSAGE FORM FOR POORLY SOLUBLE ACIDS AND AMPHOTERIC ACTIVE INGREDIENTS | Boehringer Ingelheim International GmbH (DE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023223-A2 | ORALLY ADMINISTRABLE DOSAGE FORM FOR POORLY SOLUBLE ACIDS AND AMPHOTERIC ACTIVE INGREDIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20050053669-A1 | Administration form for the oral application of poorly soluble acidic and amphorteric drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217431-A1 | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | TBXA2R, PTGES2, PTGER2 | TBXA2R 1/4885TBXAS1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.